Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Protagonist disclosed the FDA issued a letter of intent to rescind the status for rusfertide based on concerns first raised in a clinical hold placed on the drug.
Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Genentech (Roche)’s Avastin.
Ubix Therapeutics has announced a collaboration agreement with SK Biopharmaceuticals, and Engitix and Takeda are teaming up to develop a therapeutic for fibrostenotic IBD.
The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
Typical metabolic syndrome treatment includes a healthy diet, exercise, and possibly metformin, but soon, there may be a new treatment. For that and more research news, continue reading.
Philip Kantoff, CEO of Convergent Therapeutics, spoke to BioSpace before the American Association for Cancer Research Annual Meeting on April 8-13 about CONV01-α.
ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.
Cambridge, Massachusetts-based life sciences firm Flagship Pioneering announced that Michael Severino, who will leave AbbVie on May 31, is joining Flagship as a CEO-Partner.
Companies like Chameleon Biosciences and Code Biotherapeutics will present their latest research at the FUTURES 2022 conference hosted by CureDuchenne.
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
This year’s AACR Annual Meeting is coming to a close, and there has been a wealth of information and data presented. One topic of discussion stood out—mutations.
Companies working on cell therapies got most of the funding in the life sciences venture capital world this week. For that and more, continue reading.